Promosyon programı Ligand Pharms Inc Cvr
Genişletilmiş Program
Basit Program
Seviye
Hafife alma
| İsim |
Anlam |
Seviye |
| P/S |
0.000252 |
10 |
| P/BV |
5.1E-5 |
10 |
| P/E |
0.0046 |
10 |
Yeterlik
| İsim |
Anlam |
Seviye |
| ROA |
1.05 |
1 |
| ROE |
1.18 |
1 |
| ROIC |
0 |
0 |
Temettü
| İsim |
Anlam |
Seviye |
| Temettü getirisi |
0 |
0 |
| DSI |
0.5 |
5 |
| Temettülerin ortalama büyümesi |
0 |
0 |
Görev
| İsim |
Anlam |
Seviye |
| Debt/EBITDA |
0.1655 |
10 |
| Debt/Ratio |
0.0075 |
10 |
| Debt/Equity |
0.1341 |
10 |
Büyüme darbesi
| İsim |
Anlam |
Seviye |
| Gelir, milyar, % |
-10.35 |
0 |
| Ebitda, % |
17.01 |
3 |
| EPS, % |
-368.82 |
0 |
Fiyat
|
Fiyat |
Min. |
Maksimum. |
Değiştirmek |
Sektördeki değişiklikler |
Dizindeki değişiklikler |
| Dün |
0.002 $ |
0 $ |
0 $ |
0 % |
0 % |
0 % |
| Hafta |
0.002 $ |
0 $ |
0 $ |
0 % |
0 % |
0 % |
| Ay |
0.0038 $ |
0 $ |
0 $ |
-47.37 % |
0 % |
0 % |
| 3 ay |
0.003 $ |
0.002 $ |
0.0038 $ |
-33.33 % |
0 % |
0 % |
| Altı ay |
0.0024 $ |
0.0006 $ |
0.0064 $ |
-16.67 % |
0 % |
0 % |
| Yıl |
0.0027 $ |
0.0006 $ |
0.0064 $ |
-25.93 % |
0 % |
0 % |
| 3 yıl |
0.0025 $ |
0.0004 $ |
0.0098 $ |
-20 % |
0 % |
0 % |
| 5 yıl |
0.0004 $ |
0.0004 $ |
0.0354 $ |
+500 % |
0 % |
0 % |
| 10 yıl |
0.0004 $ |
0.0004 $ |
0.081 $ |
+500 % |
0 % |
0 % |
| Sene başından beri |
0.0045 $ |
0.0006 $ |
0.0064 $ |
-55.56 % |
0 % |
0 % |
Şirketin yönetimi
| Amir |
İş unvanı |
Ödeme |
Doğum yılı |
| Mr. Todd C. Davis Ph.D. |
CEO & Director |
|
1961 (64 yıl) |
| Mr. Matthew E. Korenberg |
President & COO |
|
1975 (50 yıl) |
| Mr. Octavio Espinoza |
Chief Financial Officer |
|
1971 (54 yıl) |
| Mr. Andrew T. Reardon J.D. |
Chief Legal Officer & Secretary |
|
1975 (50 yıl) |
| Mr. Paul J. Hadden |
Senior Vice President of Investments & Business Development |
|
|
| Michael Jeong |
Head of Investor Relations |
|
|
| Mr. Todd Pettingill |
Director of Corporate Development |
|
|
| Dr. Keith Marschke |
Senior Vice President of Biology & Scientific Affairs |
|
|
| Dr. Vincent D. Antle |
Senior Vice President of Technical Operations & QA - Capitsol |
|
1969 (56 yıl) |
| Mr. Patrick Lucy |
Senior VP & CBO Protein Expression Business |
|
|
Şirket hakkında Ligand Pharms Inc Cvr
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.
MAX Sohbet
